

Retired Policy

Germline Genetic Testing for Gene Variants Associated With Breast Cancer in Individuals at High Breast Cancer Risk (CHEK2, ATM, and BARD1)


Policy # 00504

Original Effective Date: 07/20/2016 Retired Date: 07/01/2024

Germline Genetic Testing for Gene Variants Associated With Breast Cancer in Individuals at High Breast Cancer Risk (CHEK2, ATM, and BARD1) was retired effective 07/01/2024.

A retired medical policy is no longer active and is not utilized for coverage eligibility determination or claims processing as of the retired date.

This medical policy is being retired as a part of the collaborative partnership with Carelon MBM Genetic Testing Program. Carelon will provide genetic testing management services to ensure enforcement of genetic testing policies effective 07/01/2024.



Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.